Health Condition 1: null- Coronary Heart Disease
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: Diagnosed cases of CHD consenting to participate in clinical drug trial program were included in the study. These CHD patient showing dyslipidemia, atherosclerotic, ischemic changes, elevated homocysteine and inflammatory markers, concentration with certain psychological complaints mainly sleep disturbances were treated with test formulation. The diagnosis of CHD patients were done on the basis of clinical as well as laboratory findings.
Exclusion criteria
Exclusion criteria: Patients suffering from chronic illness like T.B., Rheumatoid arthritis, diagnosed IHD cases; Type-1 diabetic patients; Evidence of hypo or hyperthyroidism; Age above 75 years.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The test formulation has shown Cardio-protective property through its anti-atherosclerotic, anti-inflammatory, anti-obesity activityTimepoint: Parameters measured at baseline (initial), 3 months and 6 months | — |
Secondary
| Measure | Time frame |
|---|---|
| The test formulation has shown reduction in anxiety level as well as improved sleep pattern among CHD patientsTimepoint: Parameters measured at baseline (initial), 3 months and 6 months | — |
Countries
India
Contacts
Interdisciplinary School of Indian System of Medicine